SC

SCYNEXIS

- NASDAQ:SCYX
Last Updated 2024-04-26

LinkedIn Profile

Access SCYNEXIS historical Linkedin company profile data on number of followers, employee headcount and more

Rows

Open dataset
Ticker Symbol Entity Name As Of Date Company Name Followers Employees on Linkedin Link Industry Date Added Date Updated Description Website Specialities Logo HQ.Street HQ.City HQ.State HQ.Country HQ.Postal Headcount change in past 24 months Company Name Sector Industry
nasdaq:scyx 70564 Apr 21st, 2024 12:00AM SCYNEXIS, Inc. 5.9K 61.00 Open Apr 21st, 2024 12:05AM Apr 21st, 2024 12:05AM At SCYNEXIS, we are bringing a ground-breaking class of drugs to the battle by developing innovative products that have the strength, safety, and versatility to defeat even the most insidious fungal diseases. We are committed to positively impacting the lives of patients suffering from fungal infections — from the most common to the difficult-to-treat and deadliest. (NASDAQ: SCYX) The SCYNEXIS team has deep expertise in anti-infective drug development and marketing, which can be leveraged to advance ibrexafungerp from clinical development to commercialization. Open Antifungals, Drug Development, Biotech, Infectious Disease, and Fungal Disease Open 1 Evertrust Plaza Jersey City New Jersey US 07302 SCYNEXIS Health Care Pharmaceuticals & Biotechnology
nasdaq:scyx 70564 Apr 20th, 2024 12:00AM SCYNEXIS, Inc. 5.9K 61.00 Open Apr 20th, 2024 12:02AM Apr 20th, 2024 05:37PM At SCYNEXIS, we are bringing a ground-breaking class of drugs to the battle by developing innovative products that have the strength, safety, and versatility to defeat even the most insidious fungal diseases. We are committed to positively impacting the lives of patients suffering from fungal infections — from the most common to the difficult-to-treat and deadliest. (NASDAQ: SCYX) The SCYNEXIS team has deep expertise in anti-infective drug development and marketing, which can be leveraged to advance ibrexafungerp from clinical development to commercialization. Open Antifungals, Drug Development, Biotech, Infectious Disease, and Fungal Disease Open 1 Evertrust Plaza Jersey City New Jersey US 07302 SCYNEXIS Health Care Pharmaceuticals & Biotechnology
nasdaq:scyx 70564 Apr 19th, 2024 12:00AM SCYNEXIS, Inc. 5.9K 61.00 Open Apr 19th, 2024 04:37AM Apr 19th, 2024 04:37AM At SCYNEXIS, we are bringing a ground-breaking class of drugs to the battle by developing innovative products that have the strength, safety, and versatility to defeat even the most insidious fungal diseases. We are committed to positively impacting the lives of patients suffering from fungal infections — from the most common to the difficult-to-treat and deadliest. (NASDAQ: SCYX) The SCYNEXIS team has deep expertise in anti-infective drug development and marketing, which can be leveraged to advance ibrexafungerp from clinical development to commercialization. Open Antifungals, Drug Development, Biotech, Infectious Disease, and Fungal Disease Open 1 Evertrust Plaza Jersey City New Jersey US 07302 SCYNEXIS Health Care Pharmaceuticals & Biotechnology
nasdaq:scyx 70564 Apr 18th, 2024 12:00AM SCYNEXIS, Inc. 5.9K 61.00 Open Apr 18th, 2024 12:40AM Apr 18th, 2024 06:57PM At SCYNEXIS, we are bringing a ground-breaking class of drugs to the battle by developing innovative products that have the strength, safety, and versatility to defeat even the most insidious fungal diseases. We are committed to positively impacting the lives of patients suffering from fungal infections — from the most common to the difficult-to-treat and deadliest. (NASDAQ: SCYX) The SCYNEXIS team has deep expertise in anti-infective drug development and marketing, which can be leveraged to advance ibrexafungerp from clinical development to commercialization. Open Antifungals, Drug Development, Biotech, Infectious Disease, and Fungal Disease Open 1 Evertrust Plaza Jersey City New Jersey US 07302 SCYNEXIS Health Care Pharmaceuticals & Biotechnology
nasdaq:scyx 70564 Apr 17th, 2024 12:00AM SCYNEXIS, Inc. 5.9K 61.00 Open Apr 17th, 2024 12:00AM Apr 17th, 2024 03:23PM At SCYNEXIS, we are bringing a ground-breaking class of drugs to the battle by developing innovative products that have the strength, safety, and versatility to defeat even the most insidious fungal diseases. We are committed to positively impacting the lives of patients suffering from fungal infections — from the most common to the difficult-to-treat and deadliest. (NASDAQ: SCYX) The SCYNEXIS team has deep expertise in anti-infective drug development and marketing, which can be leveraged to advance ibrexafungerp from clinical development to commercialization. Open Antifungals, Drug Development, Biotech, Infectious Disease, and Fungal Disease Open 1 Evertrust Plaza Jersey City New Jersey US 07302 SCYNEXIS Health Care Pharmaceuticals & Biotechnology
nasdaq:scyx 70564 Apr 16th, 2024 12:00AM SCYNEXIS, Inc. 5.9K 61.00 Open Apr 15th, 2024 11:56PM Apr 16th, 2024 11:39AM At SCYNEXIS, we are bringing a ground-breaking class of drugs to the battle by developing innovative products that have the strength, safety, and versatility to defeat even the most insidious fungal diseases. We are committed to positively impacting the lives of patients suffering from fungal infections — from the most common to the difficult-to-treat and deadliest. (NASDAQ: SCYX) The SCYNEXIS team has deep expertise in anti-infective drug development and marketing, which can be leveraged to advance ibrexafungerp from clinical development to commercialization. Open Antifungals, Drug Development, Biotech, Infectious Disease, and Fungal Disease Open 1 Evertrust Plaza Jersey City New Jersey US 07302 SCYNEXIS Health Care Pharmaceuticals & Biotechnology
nasdaq:scyx 70564 Apr 15th, 2024 12:00AM SCYNEXIS, Inc. 5.9K 61.00 Open Apr 14th, 2024 11:51PM Apr 15th, 2024 05:20PM At SCYNEXIS, we are bringing a ground-breaking class of drugs to the battle by developing innovative products that have the strength, safety, and versatility to defeat even the most insidious fungal diseases. We are committed to positively impacting the lives of patients suffering from fungal infections — from the most common to the difficult-to-treat and deadliest. (NASDAQ: SCYX) The SCYNEXIS team has deep expertise in anti-infective drug development and marketing, which can be leveraged to advance ibrexafungerp from clinical development to commercialization. Open Antifungals, Drug Development, Biotech, Infectious Disease, and Fungal Disease Open 1 Evertrust Plaza Jersey City New Jersey US 07302 SCYNEXIS Health Care Pharmaceuticals & Biotechnology
nasdaq:scyx 70564 Apr 14th, 2024 12:00AM SCYNEXIS, Inc. 5.9K 61.00 Open Apr 13th, 2024 11:40PM Apr 14th, 2024 11:38AM At SCYNEXIS, we are bringing a ground-breaking class of drugs to the battle by developing innovative products that have the strength, safety, and versatility to defeat even the most insidious fungal diseases. We are committed to positively impacting the lives of patients suffering from fungal infections — from the most common to the difficult-to-treat and deadliest. (NASDAQ: SCYX) The SCYNEXIS team has deep expertise in anti-infective drug development and marketing, which can be leveraged to advance ibrexafungerp from clinical development to commercialization. Open Antifungals, Drug Development, Biotech, Infectious Disease, and Fungal Disease Open 1 Evertrust Plaza Jersey City New Jersey US 07302 SCYNEXIS Health Care Pharmaceuticals & Biotechnology
nasdaq:scyx 70564 Apr 13th, 2024 12:00AM SCYNEXIS, Inc. 5.9K 61.00 Open Apr 12th, 2024 11:32PM Apr 13th, 2024 12:05PM At SCYNEXIS, we are bringing a ground-breaking class of drugs to the battle by developing innovative products that have the strength, safety, and versatility to defeat even the most insidious fungal diseases. We are committed to positively impacting the lives of patients suffering from fungal infections — from the most common to the difficult-to-treat and deadliest. (NASDAQ: SCYX) The SCYNEXIS team has deep expertise in anti-infective drug development and marketing, which can be leveraged to advance ibrexafungerp from clinical development to commercialization. Open Antifungals, Drug Development, Biotech, Infectious Disease, and Fungal Disease Open 1 Evertrust Plaza Jersey City New Jersey US 07302 SCYNEXIS Health Care Pharmaceuticals & Biotechnology
nasdaq:scyx 70564 Apr 12th, 2024 12:00AM SCYNEXIS, Inc. 5.9K 61.00 Open Apr 11th, 2024 11:38PM Apr 12th, 2024 09:01AM At SCYNEXIS, we are bringing a ground-breaking class of drugs to the battle by developing innovative products that have the strength, safety, and versatility to defeat even the most insidious fungal diseases. We are committed to positively impacting the lives of patients suffering from fungal infections — from the most common to the difficult-to-treat and deadliest. (NASDAQ: SCYX) The SCYNEXIS team has deep expertise in anti-infective drug development and marketing, which can be leveraged to advance ibrexafungerp from clinical development to commercialization. Open Antifungals, Drug Development, Biotech, Infectious Disease, and Fungal Disease Open 1 Evertrust Plaza Jersey City New Jersey US 07302 SCYNEXIS Health Care Pharmaceuticals & Biotechnology

Request a demo to view additional historical data, and much more.

Request Demo

Make fast
queries

No longer rely on engineers to access data; build and share queries with intuitive tools, and derive insights in real time.

Bookmark queries with your team

Save and share custom queries using a private bookmarking feature, accessible to your whole team.

Be first to know with alerts

Scan data points across millions of companies and receive emails when relevant metrics cross critical thresholds.

Visualize data for quick insights

Create custom keyword-based word clouds, charts, and advanced visualizations to quickly analyze the data.

Map competitor locations

Analyze competitor presence and growth over time by overlaying store locations with the Nearby Competitor feature.

Add widgets to your dashboards

Access existing maps, charts, word clouds, and other visualizations to understand your data quickly. Or build custom widgets to view data just the way you want it.